PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
3.62%
ROE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.06%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
3.50%
ROA exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.31%. Mohnish Pabrai would see if this advantage is driven by brand or cost leadership.
-0.14%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 1.06%. Seth Klarman would investigate whether a turnaround is viable.
75.34%
Gross margin 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 53.76%. Mohnish Pabrai would verify if a unique value chain offers pricing benefits.
-1.61%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 3.75%. Seth Klarman would look for a path to operational turnaround.
42.44%
Net margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.43%. Joel Greenblatt would see if this advantage is sustainable across cycles.